Predict your next investment

See what CB Insights has to offer

Investments

35

Portfolio Exits

16

About Biotechnology Investments

Biotechnology Investments Headquarter Location

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Biotechnology Investments

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Biotechnology Investments in 1 Expert Collection, including Pharma Startups.

P

Pharma Startups

5,090 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

Latest Biotechnology Investments News

Latvian-Born Investor James Richman Profits $1.8bn From His Biotechnology Investments!

Apr 27, 2020

By The Latvian-born investor James Richman has been gaining a solid amount of popularity recently, with his major investments in health and technology. While others tend to spend money on exploring space and developing sustainable energy sources, Richman’s been keen on backing other types of revolutionizing scientific ideas, mainly in the fields of biotechnology and 3D-printing. Monaco-based investor, James Richman, who is thought to have started his firm in London, is one of the billionaires at the forefront of helping combat coronavirus as he reportedly pledged $18m in the efforts to develop coronavirus treatment and vaccine. He is also mobilizing his biotechnology investments to help produce 3D-printed equipment and PPEs needed by the frontliners. He is reportedly at the forefront of backing medical breakthroughs aimed at helping combat some of the world’s silent killers. In particular, his support for the project of a group of Israeli scientists for 3D-printed hearts printed out of human cells, being the most notable one. Once the product reaches a commercial stage, it could change medicine forever and put an end to the struggles for many patients having tough luck finding donors. 3D-printing industry meeting the growing demands James Richman is said to have gained more than a $1.8 billion profit from his biotechnology investments so far, considering the recent increased demand for 3D-printed medical equipment. To many industry insiders, the news did not come as a surprise, as some of his closest friends and colleagues have compared him to the financial industry’s icon Warren Buffet, because of his foresight and risk assessment skills. Just like in 2008, the Monaco-based investor was able to foresee the crisis and make a smooth move, while others go bankrupt. His investments in 3D-printing aren’t by accident. He is thought to have started his firm in London, is one of the billionaires at the forefront of helping combat coronavirus. He is also one of the global investors who is known to have long been bullish with Asia, particularly India and China. He reportedly also pledged $18m in the efforts to develop coronavirus treatment and vaccines. He is also understood to be mobilising his biotechnology investments to help produce 3D-printed equipment and PPEs needed by the frontliners. The 3D-printed industry has be Netherlands-based 3D-printing company Heijcon is understood to be in talks with James Richman and his camp. Sources close to the matter reveal that the progress of the deal is thought to be to beef up investments in the investor’s growing biotechnology portfolio. Heijcon’s “crown jewel” is the 3D-printed bionic hands, a product, able to revolutionize the life of patients, who have lost upper limbs. Making profit in times of crisis Richman’s ability to sense events before they happen has earned him a place among the ranks of the world’s most successful investors. But he hasn’t been the only one, who has kept himself busy during the quarantine. Another hedge fund billionaire Bill Ackman made an almost 100-fold profit on his $27 million hedge. In February 2020, right before the fuss began Ackman believed that the coronavirus pandemic was about to devastate the United States’ economy and world trade markets. So he and his associates spent $27 million on all the portfolio protection they could get their hands on. In a matter of days, this investment turned into an astonishing $2.6 billion . In the meantime, the CEO of Amazon Jeff Bezos has also been experiencing increased profits to the tune of additional $24 billion , as the stock price of the US-based giant in online sales has hit an all-time high, while the company is seeing unprecedented demand. If we one looks into the history books, one can see that every once and a while a recession strikes. That’s just how the world economy works. However, one could also notice that what a crisis always does is to rearrange the status quo. And with this rearrangement, new opportunities arise. The key is to anticipate and be able to precisely understand the events and make the necessary bets. en drawing much attention to itself since the coronavirus crisis struck. The pandemic has caused a massive shortage of personal protective equipment around the globe, which could result in a health-care catastrophe in numerous countries. This is where 3D-printing comes in, as various companies, engaged in the business, have been using their technologies to manufacture different necessities for the health-care professionals, such as nasal swabs, filtering face masks , face shields, and others. Share this:

Biotechnology Investments Investments

35 Investments

Biotechnology Investments has made 35 investments. Their latest investment was in Ciblex as part of their Convertible Note on March 3, 2000.

CBI Logo

Biotechnology Investments Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

3/22/2000

Convertible Note

Ciblex

$1.3M

No

Domain Associates, and Undisclosed Investors

1

4/23/1999

Unattributed VC

TerraGen Discovery

$5.39M

Yes

BDC Venture Capital, Lumira Ventures, MDS Pharma Services, and SR One

12/4/1998

Unattributed VC

OraPharma

$16M

Yes

2/28/1998

Series A

Subscribe to see more

$99M

Subscribe to see more

10

11/4/1997

Growth Equity - II

Subscribe to see more

$99M

Subscribe to see more

10

Date

3/22/2000

4/23/1999

12/4/1998

2/28/1998

11/4/1997

Round

Convertible Note

Unattributed VC

Unattributed VC

Series A

Growth Equity - II

Company

Ciblex

TerraGen Discovery

OraPharma

Subscribe to see more

Subscribe to see more

Amount

$1.3M

$5.39M

$16M

$99M

$99M

New?

No

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Domain Associates, and Undisclosed Investors

BDC Venture Capital, Lumira Ventures, MDS Pharma Services, and SR One

Sources

1

10

10

Biotechnology Investments Portfolio Exits

16 Portfolio Exits

Biotechnology Investments has 16 portfolio exits. Their latest portfolio exit was Biotrin International on July 24, 2003.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

7/24/2003

Acquired

Undisclosed Investors

1

8/8/2000

Acquired

$991

Cubist Pharmaceuticals

1

3/9/2000

IPO

$991

Public

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

Date

7/24/2003

8/8/2000

3/9/2000

00/00/0000

00/00/0000

Exit

Acquired

Acquired

IPO

Subscribe to see more

Subscribe to see more

Companies

Subscribe to see more

Subscribe to see more

Valuation

$991

$991

Acquirer

Undisclosed Investors

Cubist Pharmaceuticals

Public

Subscribe to see more

Subscribe to see more

Sources

1

1

10

10

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.